Company profile

Shenzhen Pregene Biopharma Co., Ltd.

Privately held: no public share price (Privately-held Shenzhen CAR-T/CAR-NK biopharma; out-licensed anti-BCMA candidate PRG-1801 to Dr. Reddy's Laboratories for India rights ($162.5M deal, prnewswire). No public listing found (en.pregene.com, BioCentury, Bloomberg private-company profile). Sources: https://clinicaltrials.gov/study/NCT05652530 Entity resolved by asset-pipeline-v2.)

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
BCMA CAR-NK (Shenzhen Pregene Biopharma)
Phase 1
BCMACell therapy
Multiple Myeloma

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.